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Background: The EVEREST II REALISM Continued Access study (REALISM) is a prospective, multi-center, continued access study to collect data 
on the “real world” use of the MitraClip device in both high and non-high surgical risk patients. Enrollment in the non-high risk arm was initiated in 
January 2009 at the conclusion of the EVEREST II Randomized Controlled Trial (RCT) to allow patients continued access to the therapy. Enrollment 
was closed in April 2011. As of April 2012, all 272 non-high risk patients completed 1-year follow-up. Complete 1-year safety and effectiveness 
results as well as a comparison with the EVEREST II RCT will be presented.
methods: Patients with 3+ or 4+ mitral regurgitation (MR) were enrolled. Pre- and post-procedure and follow-up echos for all patients were 
evaluated by an independent core lab. Acute procedural safety results at 30 days and survival at 12 months are summarized. Effectiveness results, 
defined by reduction in MR and improvement in clinical outcomes, based on changes in NHYA Class and quality of life are reported.
results: Although eligibility criteria were similar between the EVEREST II RCT and the non-high risk arm of the REALISM study, patients enrolled in 
the latter were older and more co-morbid. Mean age of patients enrolled in non-high risk REALISM was 74 ±11 years vs. 67±13 in EVEREST II RCT. 
Degenerative MR was present in 69% and functional MR in 31% compared to 73% and 27%, respectively in EVEREST II RCT. Freedom from mortality 
at 12 months was 91.0% (EVEREST II RCT was 93.7%). Importantly, freedom from mitral valve surgery at 12 months was 90.1% which was improved 
from 80% in the EVEREST II RCT. Consistent with the EVEREST II RCT, a majority of patients experienced MR reduction to ≤2+ at 12 months with 
associated LV remodeling. In addition, 92% of patients in NYHA Class I/II at 12 months and scores for the physical and mental components of the 
SF-36 improved between baseline and 12 months.
conclusion: The MitraClip procedure resulted in significant and durable improvements in MR severity, LV remodeling, and clinical outcomes, and 
the required rates of mitral valve surgery post-index procedure in the non-high risk REALISM were lower than those observed in the EVEREST II RCT.
